- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/5395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
Patent holdings for IPC class A61K 31/5395
Total number of patents in this class: 170
10-year publication summary
|
14
|
12
|
15
|
9
|
16
|
13
|
20
|
10
|
12
|
1
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bow River LLC | 21 |
12 |
| Bayer AG | 3045 |
8 |
| The Broad Institute, Inc. | 1584 |
8 |
| Principia Biopharma Inc. | 187 |
7 |
| The Regents of the University of California | 18943 |
6 |
| Dana-Farber Cancer Institute, Inc. | 2455 |
5 |
| Merck Sharp & Dohme Corp. | 2247 |
4 |
| Abbvie Inc. | 1808 |
4 |
| Eli Lilly and Company | 3645 |
4 |
| BASF SE | 19740 |
3 |
| AstraZeneca AB | 3042 |
3 |
| Bayer Pharma AG | 1096 |
3 |
| Curofin Pharma GmbH | 10 |
3 |
| Zevra Denmark A/S | 37 |
3 |
| Bayer Healthcare AG | 271 |
2 |
| Board of Regents, The University of Texas System | 5370 |
2 |
| Abbott Products GmbH | 9 |
2 |
| University of Florida Research Foundation, Inc. | 3883 |
2 |
| Asahi Kasei Pharma Corporation | 144 |
2 |
| CytRx Corporation | 14 |
2 |
| Other owners | 85 |